A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Novartis website. The digital and interactive version of the Annual Review is available here. In the firm's earnings report filed July 30 for the second quarter ending June 30, 2019, the company reported total revenue of $5.871 billion for Q2/19, of which $5.574 billion was from product sales. Core operating income was USD 3.3 billion (+9%, +18% cc) mainly driven by higher Innovative Medicines sales and improved gross margin, partly offset by growth and launch investments, including for Zolgensma. Torrent Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. As of Q1 2019, the long-term credit rating for the company is A1 with Moody's Investors Service and AA- with S&P Global Ratings. La Belgique est l'un des nombreux pays à bénéficier de ce don. Net sales in 2019 are expected to grow mid-single digit (cc). [3]  The brand name Zolgensma has been provisionally approved by the FDA for the investigational product AVXS-101 (onasemnogene abeparvovec-xioi), but the product itself has not received marketing authorization or BLA approval from any regulatory authorities. The results of this business are included in continuing operations until the time of the divestment. Our Annual Report 2019 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results. The Annual Review explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2019. [6]  The brand name Zolgensma has been provisionally approved by the FDA for the investigational product AVXS-101 (onasemnogene abeparvovec-xioi), but the product itself has not received marketing authorization or BLA approval from any regulatory authorities. Core operating income guidance revised upwards: expected to grow high single digit (cc). This is a decrease of some four billion U.S. dollars compared to the year before. Innovative Medicines net sales were USD 8.8 billion (+5%, +10% cc) in the first quarter, as Pharmaceuticals BU grew 11% (cc) mainly driven by Cosentyx and Entresto, and Oncology BU grew 9% (cc) mainly driven by Lutathera, Promacta and Kisqali. In the same quarter, 13.8 million shares (for an equity value of USD 0.5 billion) were delivered as a result of options exercised and share deliveries related to participation plans of associates. Novartis Institutes for BioMedical Research, 2019 Q4 and Full Year Results Presentation & Transcript. The previously announced share buyback of up-to USD 5 billion in June 2018 is expected to be completed in 2019. 2019 à 19 ... elles représentent un complément de revenu pour le trentenaire. Third Sandoz biosimilar approved in Canada in past 11 months expanding its biosimilars portfolio to six and highlighting Sandoz commitment to broadening access to biosimilars. [1]  Constant currencies (cc), core results and free cash flow are non-IFRS measures. Core net income was USD 2.8 billion (+5%, +13% cc) as growth in core operating income was partly offset by the discontinuation of core income from the GSK consumer healthcare joint venture. PDF document. L’inflammation et les problèmes respiratoires … Readers should not rely upon the information in these pages as current or accurate after their publication dates. Download the media releaseEnglish (PDF 0.1 MB )  |  Deutsch (PDF 0.1 MB)  |  Français (PDF 0.1 MB), Watch the media webcast 09:30 CET - 08:30 GMT - 03:30 EST, Download the media presentation (PDF 1.2 MB), Watch the investor webcast14:00 CET - 13:00 GMT - 08:00 EST, Download the investor presentation (PDF 3.6 MB). The estimated impact of exchange rates on our results is provided monthly on our website. 2019 revenue: $47.45 billion 2018 revenue: $44.75 billion Headquarters: Basel, Switzerland. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. He will be a member of the Executive Committee of Novartis and report to Vas Narasimhan, CEO, Novartis. In addition, Richard oversees the commercial digital platforms across all of GSK's pharmaceutical franchises. English (PDF 8.0 MB) | Deutsch (PDF 8.0 MB). Also in Q1 2019, Novartis repaid the USD 3.0 billion, 5.125% coupon bond issued in February 2009 at maturity. 339 kb EN Invitation Full-Year 2019 Results. Additional information is provided on Novartis divisions and pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found at.https://www.novartis.com/investors/event-calendar. For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2019. The guidance above includes the forecast assumption that no Gilenya generics enter in 2019 in the US. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. You should not place undue reliance on these statements. Richard Saynor, currently SVP Classic & Established Products, Commercial & Digital Platforms at GSK, brings over 20 years of global leadership experience spanning both generics and established pharmaceutical brands. Donepezil acts as a centrally acting reversible acetylcholinesterase inhibitor. The total number of shares outstanding increased by 11.6 million versus December 31, 2018. As of March 31, 2019, the net debt increased by USD 5.3 billion to USD 21.5 billion versus December 31, 2018. Barring unforeseen events . Free cash flow for the total Group amounted to USD 1.8 billion. Operating income was USD 2.2 billion (-5%, +4% cc) driven by higher Innovative Medicines sales and improved gross margin, partly offset by growth investments, a net impairment charge and lower divestment gains. Richard has also built and led successful teams and organizations with a strong focus on inclusive culture and developing talent. With our strong pipeline, focus on productivity, and commitment to cultural transformation, we are well positioned for growth in 2019 and the future.". See page 32 of the Condensed Interim Financial Report for a full explanation. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "guidance," "transformation," "continued," "potential", "launches," "on track" "launched," "filed," "launch," "expected," "to grow," "will," "enter," "pipeline," "commitment," "well positioned," "future," "strategy," "priorities," "embrace," "deliver," "go big," "build," "allows," "expect," "to be completed,"  "closing conditions," "committed," "continued," "growth drivers," "Priority Review Voucher," "submissions," "filings," "to be presented," "potentially," "if approved," "aims," "outlook," "unforeseen," "forecast," "may," "would," "continues," "aiming," "vision," "priority review," "PRIME designation," "Sakigake designation," "enrollment," "planned," "upcoming," "Fast Track designation," "Orphan designation," "scheduled," or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products; or regarding the potential outcome, or financial or other impact on Novartis, of the spinoff of our Alcon Division, or of the proposed divestiture of certain portions of our Sandoz Division business in the US; or regarding the potential impact of the share buyback plan; or regarding potential future sales or earnings of the Group or any of its divisions or potential shareholder returns; or by discussions of strategy, plans, expectations or intentions. Richard is a Pharmacist by training and started his pharma business career as a sales representative at G.D. Searle in the U.K. Underpinning our financial results in the first quarter is a continued focus on key growth drivers including: Net sales of the top 20 Innovative Medicines products in Q1, Strengthen R&D - Key developments from the first quarter, Results from ongoing trials and other highlights. Excluding the US, net sales grew 4% (cc). Boucherville, December 17, 2020 – Sandoz Canada Inc. announced today that Health Canada has authorized Hyrimoz ® (adalimumab injection, reference biologic drug: Humira ®) on November 4, 2020 for marketing in … In order to comply with International Financial Reporting Standards (IFRS), Novartis has separated the Group's reported financial data for the current and prior years into "continuing" and "discontinued" operations. Sales of Enbrel in Q2/19 were $1.363 billion worldwide, representing 24.45% of the firms product revenues and its largest individual patented drug by revenue. If mid-April exchange rates prevail for the remainder of 2019, the currency impact for the year would be negative 3 percentage points on net sales and negative 3 to 4 percentage points on core operating income. In 2019, Novartis AG made approximately 38.5 billion U.S. dollars from its pharmaceuticals business segment. Sandoz fait don d’hydroxychloroquine à la Belgique. Generic competition had a negative impact of 1 percentage point (cc). As part of the spin off, Alcon incurred total bank debt of approximately USD 3.5 billion and paid approximately USD 3.1 billion in cash, including payment in satisfaction of certain intercompany indebtedness owed by Alcon and its subsidiaries to Novartis and its affiliates. At the beginning of 2019, ... Sandoz Targets 40 First-To-File Opportunities In The US. Le choix en question est … Sandoz net sales were USD 2.3 billion (-8%, -2% cc) in the first quarter as 9 percentage points (cc) of price erosion mainly in the US, were partially offset by volume growth of 7 percentage points (cc). Novartis aims to offset the dilutive impact from equity based participation plans of associates over the remainder of the year. From a divisional perspective, we expect net sales performance (cc) in 2019 to be as follows: In particular, our expectations could be affected by, among other things: global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the proposed transactions or the development of the products described in this release; the potential that the strategic benefits, synergies or opportunities expected from the Alcon and Sandoz transactions may not be realized or may be more difficult or take longer to realize than expected; the inherent uncertainties involved in predicting shareholder returns; the uncertainties inherent in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and will continue this year; safety, quality or manufacturing issues; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential litigation with respect to the proposed transactions, product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes and government investigations generally; uncertainties involved in the development or adoption of potentially transformational technologies and business models; our performance on environmental, social and governance measures; general political, economic and trade conditions, including uncertainties regarding the effects of ongoing instability in various parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Net sales were USD 11.1 billion (+2%, +7% cc) in the first quarter driven by volume growth of 11 percentage points (cc), mainly from Cosentyx, Entresto, Lutathera, Promacta and Kisqali. Novartis has appointed Richard Saynor as CEO of Sandoz effective no later than August 1, 2019. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2019. Novartis a promis un don mondial allant jusqu’à 130 millions de doses d’hydroxychloroquine, un antipaludique, afin d’apporter son soutien à la lutte contre la pandémie du COVID-19. He currently manages a USD 10 billion Established Products portfolio which comprises over 350 brands commercialized in over 120 countries. Results for discontinued operations in the first quarter of 2019 include a full quarter of results from the Alcon Division and certain Corporate costs directly attributable to Alcon. During his career, Richard has established a successful track record building strong interfaces between commercial and technical operations as well as driving commercial excellence across his organization. Revenue Annual and half yearly information News & announcement Next. Core operating income margin in constant currencies increased by 2.6 percentage points; currency had a negative impact of 0.6 percentage points, resulting in a net increase of 2.0 percentage points to 29.3% of net sales. The commentary below focuses on continuing operations including the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions. We also provide information on discontinued operations. In Q1 2019, Novartis repurchased a total of 2.2 million shares for USD 0.2 billion, including 0.8 million shares (USD 0.1 billion) bought back under the up-to USD 5 billion share buyback announced in June 2018 on the SIX Swiss Exchange second trading line and 1.4 million shares (USD 0.1 billion) repurchased from associates. Bâle, le 16 juillet 2020 - Sandoz a annoncé aujourd’hui une nouvelle opération visant à faciliter aux patients des pays à faible revenu (PFR) et à revenu intermédiaire inférieur (PRITI) l’accès à des médicaments à des prix abordables pour traiter les principaux symptômes du COVID-19, un besoin essentiel en l’absence de vaccin ou de traitement curatif. Sandoz SAS est la filiale médicaments génériques et biosimilaires du groupe Novartis en France. In 2019, the Swiss pharmaceutical company Novartis AG’s total revenue amounted to just over 47 billion U.S. dollars. Novartis announces the company’s fourth quarter and 2019 full year financial results. Basel, April 24, 2019 - Commenting on the results, Vas Narasimhan, CEO of Novartis, said: "Novartis is off to a strong start in 2019 with the Mayzent launch, successful Alcon spin-off, and strong operational execution leading us to revise 2019 profit guidance upwards. Pricing had a negative impact of 1 percentage point (cc). The increase was driven by higher underlying operating profit and a €0.8 billion improvement in changes in working capital, where the prior year was impacted by the disposal of our spreads business. Select a year: 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 8.10.2020. 2019 Proxy Statement (PDF 1.98 MB) PDF Format Download (opens in new window) 2018 Annual Report (PDF 1.63 MB) PDF Format Download (opens in new window) 2016 . Novartis revenue breakdown by business segment: 20.5% from Sandoz and 79.5% from Innovative Medicines. A replay will be available after the live webcast by visiting.https://www.novartis.com/investors/event-calendar, Detailed financial results accompanying this press release are included in the condensed interim financial report at the link below. New focused medicines company guidance Excluding Alcon and the Sandoz US oral solids and dermatology business from both 2018 and 2019. Further language versions are available through the following links: German version is available through the following link:http://hugin.info/134323/R/2242313/884925.pdf, French version is available through the following link:http://hugin.info/134323/R/2242312/884924.pdf, This site is intended for a global audience, http://hugin.info/134323/R/2242311/884910.pdf, https://www.novartis.com/investors/event-calendar, http://hugin.info/134323/R/2242311/884922.pdf, http://hugin.info/134323/R/2242313/884925.pdf, http://hugin.info/134323/R/2242312/884924.pdf, American Academy of Neurology (AAN) investor conference call, Meet Novartis Management investor event in Boston, American Society of Clinical Oncology (ASCO) investor event, Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions, Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation, Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD 307 million, +24% cc), Kisqali (USD 91 million) and Kymriah (USD 45 million), Mayzent (siponimod) launched for RMS including active secondary progressive MS (SPMS), Brolucizumab (RTH258) filed in the EU and US with PRV; launch in US expected within 2019, Zolgensma[3] (AVXS-101) new data presented at MDA supports Zolgensma as a foundation therapy, In connection with the Alcon spin-off on April 9, the Group will report as part of its Q2 discontinued operations results a one-time non-cash IFRS gain of approximately USD 4.7 billion. Our strategy is to focus Novartis as a leading medicines company with five priorities: embrace operational excellence, deliver transformative innovation, go big on data science, build trust with society, and build a new culture by unleashing the power of our people. [5]  Discontinued operations described on page 32 of the Condensed Interim Financial Report. We enter an exciting period with expected launches of Zolgensma, BYL719 and brolucizumab and multiple late stage readouts. These treasury share transactions resulted in an equity increase of USD 0.3 billion while cash inflows and outflows related to share transactions mostly offset each other. Retaining a good balance between investment in the business, a strong capital structure and attractive shareholder returns remains a priority. Net income was USD 1.9 billion, (-5%, +4% cc) broadly in line with operating income. Half yearly information. … The Corporate Fact Sheets provide a comprehensive overview of Novartis overall as well as our divisions (Innovative Medicines, Sandoz), our research organization NIBR, and outline our commitment to associates as well as Corporate Responsibility. Novartis revenue breakdown by geographic segment: 5.6% from Japan , 34.3% from United States, 5.1% from France, 8.7% from Germany and 46.3% from Other However, generic competitors may still launch at risk. [1] Continuing operations include the businesses of Innovative Medicines and Sandoz divisions and Corporate activities and discontinued operations include the business of Alcon. Net sales in 2019 are expected to grow mid-single digit (cc). In 2019, Sandoz has generated revenue of $9.73B from its generic segment. [2]  Refers to continuing operations as defined on page 32 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions. [4]  Removes Alcon and the Sandoz US dermatology and oral solids portfolio from both 2019 and 2018. Novartis will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. reSET-O, cleared by the US Food and Drug Administration (FDA) in December, is immediately available. EPS was USD 0.81 (-5%, +5% cc) in line with net income. Core EPS was USD 1.21 (+5%, +13% cc) in line with core net income.